A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression.
There is an urgent and unmet need for accurate biomarkers in Amyotrophic Lateral Sclerosis. A pharmaco-metabolomics study was conducted using plasma samples from the TRO19622 (olesoxime) trial to assess the link between early metabolomic profiles and clinical outcomes. Patients included in this tria...
Uloženo v:
